Biotech Values

[rfj1862]

If the FDA ends up rejecting MDGL’s NASH NDA it’s unclear what effect that would have on VKTX, but it’s not crazy to be concerned that VKTX might incur a steep sell-off.

Actually just thinking about this -- yes it would incur a steep sell-off, but it would also give VKTX the opportunity to design their Phase 3 accordingly, which would then make them first to market if the trial was a success.

I view this whole scenario as exceedingly unlikely but it could actually be ultimately to VKTX's benefit.

In any case I expect VKTX will be off the market in relatively short order.